Notice NOT-DK-17-019 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DA-18-016 from the NIH Guide for Grants and Contracts. This initiative will support exploratory projects that exploit HIV or host genomic or nucleomic information to understand HIV latency in individuals with substance use disorders (SUDs).

Notice NOT-HL-17-359 from the NIH Guide for Grants and Contracts

Notice NOT-OD-17-113 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-17-484 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to support collaborative research between Tribal Epidemiology Centers and extramural investigators on topics related to minority health and health disparities in American Indian / Alaska Native (AI/AN) populations.

Funding Opportunity PAR-17-483 from the NIH Guide for Grants and Contracts. The purpose of this initiative is to support collaborative research between Tribal Epidemiology Centers and extramural investigators on topics related to minority health and health disparities in American Indian / Alaska Native (AI/AN) populations.

Funding Opportunity PAR-17-482 from the NIH Guide for Grants and Contracts. NHGRI invites applications for research developing comparative approaches that can be used to understand genome structure and function and the relationship between genomic features and phenotypes. This program supports studies that enable the use of a diverse array of species to advance our ability to understand basic biological processes related to human health and disease, as well as studies that develop novel analytical tools and resources for the comparative genomics research community.

Funding Opportunity RFA-AI-17-036 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to support screening of target-based pharmaceutical libraries to identify candidate therapeutics against select eukaryotic pathogens and subsequent preclinical development activities.

Funding Opportunity PA-17-481 from the NIH Guide for Grants and Contracts. The purpose of this individual postdoctoral research training fellowship is to enhance the research training of promising postdoctoral candidates who have the potential to become productive, independent investigators in health services research, with a research interest in areas and priorities relevant to the mission of AHRQ.

Funding Opportunity RFA-AI-17-028 from the NIH Guide for Grants and Contracts. The objective of this Funding Opportunity Announcement (FOA) is to support the development of new and innovative multipurpose prevention technologies (MPT) with rheological/biophysical properties and product user perceptions compatible with current long-acting reversible contraceptive (LARC) strategies (look, feel, effectiveness, safety and duration of action) for the dual purpose of preventing pregnancy and HIV infection in women. MPTs proposed for development must be dual indication and prevent pregnancy and HIV infection and have drug delivery systems (DDS) capable with sustained/extended release of both drugs. MPTs proposed for development must use a licensed contraceptive. This FOA requires an industry partner, milestones linked to Go/No Go decisions and year 5 funding requires submission of a pre-IND application to the FDA.

Notice NOT-AI-17-041 from the NIH Guide for Grants and Contracts

Notice NOT-NS-18-008 from the NIH Guide for Grants and Contracts

Notice NOT-OD-17-105 from the NIH Guide for Grants and Contracts

Notice NOT-TR-17-023 from the NIH Guide for Grants and Contracts

Notice NOT-OD-17-108 from the NIH Guide for Grants and Contracts

Notice NOT-EB-17-011 from the NIH Guide for Grants and Contracts

Notice NOT-OH-17-012 from the NIH Guide for Grants and Contracts

Notice NOT-OD-17-111 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-17-480 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support the next stage of development for projects requiring approval from a Federal regulatory agency or for those projects developing complex research tools. The FOA aims to facilitate the transition of previously funded SBIR and STTR Phase II projects to the commercialization stage by promoting partnerships between NIHs SBIR/STTR awardees and third-party investors and/or strategic partners. Consistent with the goals of this funding initiative and as required by the SF424 instructions for all SBIR Phase II applications, applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the project period. It is expected that the level of this independent third-party funding will equal or exceed the NINDS funds being requested throughout the SBIR Phase IIB project period.

Funding Opportunity PAR-17-479 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that seek additional funding to support clinical trials for projects that were previously funded by NIH SBIR and STTR Phase II awards. The projects must focus on products related to the mission and goals of the National Institute of Neurological Disorders and Stroke (NINDS) and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Since conducting the clinical trials needed for commercialization may be capital-intensive, the FOA aims to facilitate the transition of SBIR Phase II projects to the commercialization stage by promoting partnerships between NIHs SBIR/STTR awardees and third-party investors and/or strategic partners. Consistent with the goals of this funding initiative and as required by the SF424 instructions for all SBIR Phase II applications, applicants must submit a Commercialization Plan, which should include details on any independent third-party investor funding that has already been secured or is anticipated during the project period. It is expected that the level of this independent third-party funding will equal or exceed the NINDS funds being requested throughout the SBIR Phase IIB project period.